

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Transcenta Holding Limited**

**創勝集團醫藥有限公司**

*(registered by way of continuation in the Cayman Islands with limited liability)*

**(Stock Code: 6628)**

### **DATE OF BOARD MEETING**

The board of directors (the “**Board**”) of Transcenta Holding Limited (the “**Company**”, and its subsidiaries, the “**Group**”) hereby announces that a meeting of the Board of the Company will be held on March 21, 2022 for the purpose of considering and approving the annual results of the Group for the year ended December 31, 2021 and the recommendation of a final dividend, if any, and transacting any other business.

By Order of the Board  
**Transcenta Holding Limited**  
**Xueming Qian**  
*Executive Director and  
Chief Executive Officer*

Hong Kong, March 8, 2022

*As at the date of this announcement, the board of directors of the Company comprises Dr. Xueming Qian as executive Director and chief executive officer, Dr. Michael Ming Shi and Mr. Albert Da Zhu as executive Directors, Dr. Yining (Jonathan) Zhao as chairman and non-executive Director, and Mr. Jiasong Tang, Dr. Jun Bao and Mr. Zhihua Zhang as independent non-executive Directors.*